AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.

Soraya AllasAssumpta CaixàsChristine PoitouMuriel CoupayeDenise ThuilleauxFrançoise LorenziniGwenaëlle DieneAntonino CrinòFrédéric IllouzGraziano GrugniDiane PotvinSarah BocchiniThomas DelaleThierry AbribatMaithé Tauber

Published in: PloS one (2018)

AZP-531 may constitute a new treatment strategy to improve hyperphagia and metabolic issues in patients with PWS. These findings support further investigation in longer-term clinical trials.

Keyphrases

clinical trial
growth hormone
preterm infants
double blind
study protocol
combination therapy
human health
phase ii